Vyxeos(CPX-351) in Adults w R/R Acute Lymphoblastic Leukemia
Status:
Active, not recruiting
Trial end date:
2022-10-01
Target enrollment:
Participant gender:
Summary
This study involves Vyxeos (CPX-351), a formulation of a fixed combination of the two
anti-tumor drugs, cytarabine and daunorubicin that will be given as an infusion over 90
minutes. This study will use what is called a "liposome" injection. This is a special fat
capsule (called a liposome) that surrounds the cytarabine and daunorubicin and protects the
drugs from being eliminated/destroyed by the body.
Phase:
Phase 2
Details
Lead Sponsor:
H. Lee Moffitt Cancer Center and Research Institute